Aeterna Zentaris Inc. announces the appointment of David A. Dodd to the role of president and CEO. Dodd has also been appointed director on the board of directors.
Dodd has more than 35 years’ executive management experience in the pharmaceutical and biotechnology industry. Dodd has been president, CEO and chairman of BioReliance Corporation; non-executive chairman of Stem Cell Sciences Plc.; president, CEO and director of Serologicals Corporation; and CEO of Solvay Pharmaceuticals Inc., and chairman of its subsidiary Unimed Pharmaceuticals Inc. Prior to his executive positions, Dodd held various senior management positions at Wyeth-Ayerst Laboratories, the Mead Johnson Laboratories Division at Bristol-Myers Squibb, and Abbott Laboratories.
Currently he serves as chair, board of directors, of GeoVax Inc.; director on the board of Aruna Biomedical; and as a director on the board of PNP Therapeutics. Dodd is also the CEO of RiversEdge BioVentures LLC, which he founded in 2009.
Dodd is an accomplished speaker at both business development and pharmaceutical conferences. He holds many awards including the Oglethorpe Award for UK-US Business Relationships, the Georgia BIO Industry Growth Award, and the FastTech 50 Growth Company Award.
Dodd holds a bachelor of science and master of science degrees from Georgia State University, and completed the Harvard Business School of Advanced Management program.
Leave a Reply